Found 5 results
Filters: Keyword is Multiple Sclerosis, Chronic Progressive  [Clear All Filters]
2022
RĂșa SMHurtado, Kaunzner UW, Pandya S, Sweeney E, Tozlu C, Kuceyeski A, Nguyen TD, Gauthier SA.  2022.  Lesion features on magnetic resonance imaging discriminate multiple sclerosis patients.. Eur J Neurol. 29(1):237-246.
Pitt D, Lo CHung, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PLawrence, Wesley S et al..  2022.  Toward Precision Phenotyping of Multiple Sclerosis.. Neurol Neuroimmunol Neuroinflamm. 9(6)
2018
Kang Y, Schlyer D, Kaunzner UW, Kuceyeski A, Kothari PJ, Gauthier SA.  2018.  Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195.. PLoS One. 13(8):e0201289.
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT et al..  2018.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.. N Engl J Med. 379(9):846-855.
2016
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..  2016.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.